{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:13:05Z","timestamp":1790140385580,"version":"4.0.1"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The association between the use of bone-modifying agents (BMAs) and the outcomes among patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with abiraterone acetate plus prednisone (AAP) remains unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the association between BMA use and the outcomes of patients with mCSPC receiving AAP.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this cohort study, a post hoc analysis of individual participant data from the LATITUDE trial was performed. The LATITUDE trial, a phase 3 randomized clinical trial, aimed to assess the efficacy of AAP and androgen deprivation therapy (ADT) vs dual-placebo and ADT in patients with high-risk mCSPC (data cutoff, August 15, 2018). Eligible patients had newly diagnosed prostate cancer with metastases and at least 2 of 3 high-risk factors (Gleason score \u22658, presence of \u22653 lesions on bone scan, or presence of measurable visceral metastasis). The trial was conducted at 235 sites in 34 countries. Data for the present study were evaluated from July 18 to September 23, 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Use of BMAs was defined as the administration of bisphosphonates and denosumab within 90 days before and after randomization.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes were time to skeletal-related events (SREs) and overall survival (OS). An SRE was defined as a clinical or pathological fracture, spinal cord compression, palliative radiation to bone, or surgery involving bone. Differences in these outcomes were examined using the restricted mean survival time from inverse probability of treatment weighting\u2013adjusted Kaplan-Meier curves, estimated until the last event was observed (longest time observed, 63.9 months). Treatment \u00d7 covariate interactions were analyzed using weighted Cox proportional hazards regression models for the total cohort.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In the total cohort of 1199 patients (956 [79.7%] younger than 75 years), 597 (49.8%) received AAP and ADT, including 474 (79.4%) younger than 75 years and 384 (64.3%) with more than 10 bone metastases (AAP cohort); 602 (50.2%) were treated with dual placebo and ADT, including 482 (80.1%) younger than 75 years and 377 (62.6%) with more than 10 bone metastases (ADT cohort). In the AAP cohort, 132 patients (22.1%) received BMAs, while in the ADT cohort, 131 (21.8%) did. Zoledronic acid was the most frequently administered BMA in both the AAP (93 [70.5%]) and the ADT (88 [67.2%]) cohorts. During the median follow-up of 51.8 (IQR, 47.2-57.0) months in the AAP cohort, BMA use was associated with a longer time to SRE (difference, 7.8 [95% CI, 4.2-11.3] months) but not with OS (difference, 1.6 [95% CI, \u22122.5 to 5.8] months). In the ADT cohort, BMA use was associated with both time to SRE (difference, 9.3 [95% CI, 5.2-13.3] months) and OS (difference, 5.5 [95% CI, 3.2-9.8] months). No evidence was found that the outcomes of BMA varied by AAP or ADT (hazard ratio for time to SRE, 0.99 [95% CI, 0.48-2.08];\n P<\/jats:italic>\n \u2009=\u2009.99 for interaction; hazard ratio for OS, 1.31 [95% CI, 0.88-1.96];\n P<\/jats:italic>\n \u2009=\u2009.18 for interaction).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this cohort study suggest that use of BMAs was associated with a longer time to SRE in patients with high-risk mCSPC treated with ADT, with or without AAP, suggesting that BMA use might provide benefits to this population.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.2467","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T11:31:23Z","timestamp":1710502283000},"page":"e242467","source":"Crossref","is-referenced-by-count":19,"title":["Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate"],"prefix":"10.1001","volume":"7","author":[{"given":"Wataru","family":"Fukuokaya","sequence":"first","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tsuzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"zoi240115r2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.canep.2019.05.013","article-title":"Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: a 12-year longitudinal nationwide healthcare database study.","volume":"61","author":"Baek","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"19","key":"zoi240115r3","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"9768","key":"zoi240115r4","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"zoi240115r6","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023).","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"issue":"2","key":"zoi240115r7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi240115r8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10147-016-1037-2","article-title":"A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.","volume":"22","author":"Kamba","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"zoi240115r9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi240115r10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of patients with advanced prostate cancer: part I: intermediate-\/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference 2022.","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur Urol"},{"issue":"9","key":"zoi240115r11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/oncolo\/oyad045","article-title":"Real-world treatment trends among patients with metastatic castration-sensitive prostate cancer: results from an international study.","volume":"28","author":"Barata","year":"2023","journal-title":"Oncologist"},{"issue":"10","key":"zoi240115r12","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy.","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos Int"},{"issue":"4","key":"zoi240115r13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy.","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi240115r14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi240115r16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"zoi240115r17","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.metabol.2014.09.002","article-title":"Type 2 diabetes mellitus and fracture risk.","volume":"63","author":"Dede","year":"2014","journal-title":"Metabolism"},{"issue":"4","key":"zoi240115r18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1503\/cmaj.071330","article-title":"Use of proton pump inhibitors and risk of osteoporosis-related fractures.","volume":"179","author":"Targownik","year":"2008","journal-title":"CMAJ"},{"issue":"20","key":"zoi240115r19","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-20-1876","article-title":"Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab.","volume":"26","author":"Hopkins","year":"2020","journal-title":"Clin Cancer Res"},{"key":"zoi240115r20","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00695-x","article-title":"Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials.","author":"Fukuokaya","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"zoi240115r21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","article-title":"MissForest\u2014non-parametric missing value imputation for mixed-type data.","volume":"28","author":"Stekhoven","year":"2012","journal-title":"Bioinformatics"},{"issue":"3","key":"zoi240115r22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"1","key":"zoi240115r23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"zoi240115r24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12874-020-01098-5","article-title":"Dynamic RMST curves for survival analysis in clinical trials.","volume":"20","author":"Liao","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"zoi240115r25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/jnci\/djab196","article-title":"Real-world use of bone-modifying agents in metastatic castration-sensitive prostate cancer.","volume":"114","author":"Mitchell","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"zoi240115r26","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003226.13","article-title":"MP11-13 clinical fracture incidence in metastatic hormone-sensitive prostate cancer (mHSPC) and risk-reduction following addition of zoledronic acid to androgen deprivation therapy (ADT) with or without docetaxel (DOC): long-term results from 2 phase 3 trials from the Stampede Platform Protocol.","volume":"209","author":"Jones","year":"2023","journal-title":"J Urol"},{"key":"zoi240115r1","unstructured":"Surveillance, Epidemiology, and End Results Program. Cancer stat facts: prostate cancer. Accessed September 24, 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"key":"zoi240115r5","unstructured":"European Association of Urology. Prostate cancer. 2023. Accessed September 24, 2023. https:\/\/uroweb.org\/guidelines\/prostate-cancer"},{"key":"zoi240115r15","unstructured":"ClinicalTrials.gov. A study of abiraterone acetate plus low-dose prednisone plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed participants with high-risk, metastatic hormone-na\u00efve prostate cancer (mHNPC). Updated March 13, 2023. Accessed December 24, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01715285"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2816217\/fukuokaya_2024_oi_240115_1709923038.71956.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T11:31:27Z","timestamp":1710502287000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2816217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.2467","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}